Acquired by Bristol Myers Squibb in Mar 2024
KRTX - Karuna Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
KRTX price evolution
KRTX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $185.82 | $184.57 | $263.6 | $562.92 |
| Short term investments | $1076.99 | $1157.04 | $1172.91 | $911.79 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1315.31 | $1365.4 | $1451.95 | $1507.76 |
| Long term investments | ||||
| Property, plant & equipment | $20.51 | $19.32 | $19.62 | $7.93 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $20.9 | $19.7 | $20.16 | $8.41 |
| Total investments | $1076.99 | $1157.04 | $1172.91 | $911.79 |
| Total assets | $1336.21 | $1385.1 | $1472.1 | $1516.17 |
| Current liabilities | ||||
| Accounts payable | $6.78 | $2.94 | $1.1 | $0.48 |
| Deferred revenue | ||||
| Short long term debt | $2.84 | $1.8 | $1.98 | $2.07 |
| Total current liabilities | $68.13 | $48.97 | $38.6 | $25.24 |
| Long term debt | $13.85 | $13.81 | $13.83 | $2.69 |
| Total noncurrent liabilities | $13.85 | $13.81 | $13.94 | $2.8 |
| Total debt | $16.69 | $15.61 | $15.81 | $4.76 |
| Total liabilities | $81.97 | $62.78 | $52.54 | $28.03 |
| Shareholders' equity | ||||
| Retained earnings | -$997.89 | -$884.06 | -$764.94 | -$661.78 |
| Other shareholder equity | $0.21 | -$2.93 | -$3.64 | -$1.61 |
| Total shareholder equity | $1254.23 | $1322.32 | $1419.56 | $1488.13 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $185.82 | $248.59 | $207.21 | $53.2 |
| Short term investments | $1076.99 | $875.72 | $287.04 | $269.28 |
| Net receivables | $0.06 | $1.75 | ||
| Inventory | ||||
| Total current assets | $1315.31 | $1154.77 | $517.33 | $344.6 |
| Long term investments | ||||
| Property, plant & equipment | $20.51 | $7.88 | $9.54 | $2.87 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $20.9 | $8.56 | $10.34 | $3.03 |
| Total investments | $1076.99 | $875.72 | $287.04 | $269.28 |
| Total assets | $1336.21 | $1163.33 | $527.67 | $347.63 |
| Current liabilities | ||||
| Accounts payable | $6.78 | $2.38 | $1.94 | $0.86 |
| Deferred revenue | ||||
| Short long term debt | $2.84 | $2.28 | $2.17 | $0.84 |
| Total current liabilities | $68.13 | $33.95 | $20.21 | $6.85 |
| Long term debt | $13.85 | $3.05 | $5.33 | $1.84 |
| Total noncurrent liabilities | $13.85 | $3.15 | $5.43 | $1.84 |
| Total debt | $16.69 | $5.33 | $7.5 | $2.69 |
| Total liabilities | $81.97 | $37.1 | $25.64 | $8.69 |
| Shareholders' equity | ||||
| Retained earnings | -$997.89 | -$564.21 | -$287.87 | -$144.07 |
| Other shareholder equity | $0.21 | -$3.29 | -$0.5 | $0.04 |
| Total shareholder equity | $1254.23 | $1126.24 | $502.03 | $338.93 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.65 | |||
| Cost of revenue | ||||
| Gross Profit | $0.65 | |||
| Operating activities | ||||
| Research & development | $82.19 | $103.95 | $92.49 | $85.47 |
| Selling, general & administrative | $47.39 | $32.27 | $27.42 | $24.25 |
| Total operating expenses | $129.59 | $136.22 | $119.91 | $109.72 |
| Operating income | -$129.59 | -$136.22 | -$119.91 | -$109.07 |
| Income from continuing operations | ||||
| EBIT | -$113.15 | -$119.12 | -$103.16 | -$97.57 |
| Income tax expense | $0.67 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$113.82 | -$119.12 | -$103.16 | -$97.57 |
| Income (for common shares) | -$113.82 | -$119.12 | -$103.16 | -$97.57 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.65 | $10.64 | $36.96 | |
| Cost of revenue | ||||
| Gross Profit | $0.65 | $10.64 | $36.96 | |
| Operating activities | ||||
| Research & development | $364.1 | $224.25 | $128.2 | $43.41 |
| Selling, general & administrative | $131.33 | $76.07 | $52.62 | $28.41 |
| Total operating expenses | $495.43 | $300.31 | $180.82 | $71.82 |
| Operating income | -$494.78 | -$289.68 | -$143.85 | -$71.82 |
| Income from continuing operations | ||||
| EBIT | -$433.01 | -$274.92 | -$143.8 | -$68.51 |
| Income tax expense | $0.67 | $1.42 | $0.01 | $0.04 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$433.68 | -$276.34 | -$143.81 | -$68.55 |
| Income (for common shares) | -$433.68 | -$276.34 | -$143.81 | -$68.55 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$113.82 | -$119.12 | -$103.16 | -$97.57 |
| Operating activities | ||||
| Depreciation | $0.45 | $0.46 | $0.47 | $0.33 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $22.79 | $18.3 | $18 | $15.51 |
| Total cash flows from operations | -$111.06 | -$110 | -$64.13 | -$100.63 |
| Investing activities | ||||
| Capital expenditures | -$0.8 | -$0.63 | -$0.78 | -$0.71 |
| Investments | $93.24 | $28.94 | -$252.81 | -$26.78 |
| Total cash flows from investing | $92.44 | $28.31 | -$253.58 | -$27.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $19.81 | $2.86 | $18.33 | $442.57 |
| Net borrowings | ||||
| Total cash flows from financing | $19.87 | $2.66 | $18.4 | $442.45 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.25 | -$79.03 | -$299.32 | $314.33 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$433.68 | -$276.34 | -$143.81 | -$68.55 |
| Operating activities | ||||
| Depreciation | $1.7 | $1.11 | $0.51 | $0.14 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $74.6 | $47.45 | $29.81 | $13.47 |
| Total cash flows from operations | -$385.82 | -$228.01 | -$100.88 | -$69.86 |
| Investing activities | ||||
| Capital expenditures | -$2.92 | -$0.92 | -$3.07 | -$0.42 |
| Investments | -$157.4 | -$585.48 | -$19.62 | -$89.23 |
| Total cash flows from investing | -$160.32 | -$586.39 | -$22.69 | -$89.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $483.58 | $856.22 | $277.86 | $4.06 |
| Net borrowings | ||||
| Total cash flows from financing | $483.37 | $855.78 | $277.57 | $3.66 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$62.77 | $41.38 | $154.01 | -$155.85 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 38.08M |
| Revenue | $654.00K |
|---|---|
| EBITDA | -$431.31M |
| EBIT | -$433.01M |
| Net Income | -$433.68M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -93.85% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 32.93 |
| Cash/Share | 4.88 |
| EPS | -$11.39 |
|---|---|
| ROA | -30.38% |
| ROE | -31.63% |
| Debt/Equity | 0.07 |
|---|---|
| Net debt/EBITDA | 0.24 |
| Current ratio | 19.31 |
| Quick ratio | 19.31 |